Moderate to intense exercise in childhood reduces smoking in adulthood
GlobalData estimates that by the end of 2024, there will be around 14.50 million diagnosed prevalent cases of men and…
Consumer Trends
-
-
Xgene’s non-opioid analgesic reduces pain in Phase IIb trial
Taiwanese pharmaceutical company Xgene Pharmaceutical announced that its non-opioid analgesic drug XG005 has reduced acute pain in patients after surgery…
-
Zepbound will dominate obesity market following SURMOUNT-5 results, says analyst
Following positive results from its SURMOUNT-5 trial, Eli Lilly’s Zepbound (tirzepatide) will surpass Novo Nordisk’s Weogvy (semaglutide) in the obesity…
-
UK desirability has turned a corner in clinical trials
The UK’s desirability as a clinical trial location is improving, reversing its previously downward trajectory, according to the Association of…
-
Four oral GLP-1R products in Phase III trials as race intensifies
The popularity of GLP-1 receptor (GLP-1R) subcutaneous treatments for obesity has proved the demand for the drugs, but the lack…
-
Dr Oz nominated to lead CMS despite big pharma ties
Television personality Dr Mehmet Oz has been nominated by President-elect Donald Trump Jr to lead the Centers for Medicare and…
-
Corcept’s relacorilant GRADIENT trial misses primary endpoint
Corcept Therapeutics has shared some results from its Phase III GRADIENT trial for relacorilant – its experimental treatment for Cushing’s…
-
mRNA licensing agreements surge 800% amid GSK lawsuits
mRNA-based innovator pharmaceuticals have experienced a massive increase in licensing agreement deal values following success with the technology in Covid-19…
-
EASD 2024: Mazdutide improves cardiometabolic function in overweight patients
On 10 September, at the European Association for the Study of Diabetes (EASD) 60th Annual Meeting 2024, Eli Lilly and…
-
As mpox spreads, ‘national governments have a moral responsibility to help’
As the number of mpox-related deaths in the Democratic Republic of Congo (DRC) and neighbouring countries continues to climb, international…
